The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Kartos Therapeutics
Leadership - Kartos Therapeutics
Stock and Other Ownership Interests - Kartos Therapeutics
Travel, Accommodations, Expenses - Kartos Therapeutics
Navtemadlin (KRT-232) activity after failure of anti-PD-1/L1 therapy in patients (pts) with TP53WT Merkel cell carcinoma (MCC).
 
Michael K.K. Wong
Consulting or Advisory Role - Castle Biosciences; Pfizer; Regeneron
 
Melissa Amber Burgess
Consulting or Advisory Role - Rain Therapeutics
Research Funding - Merck
Travel, Accommodations, Expenses - SpringWorks Therapeutics
(OPTIONAL) Uncompensated Relationships - TRACON Pharma
 
Sunandana Chandra
Honoraria - Array BioPharma; Bristol Myers Squibb; EMD Serono; Exicure; Novartis; Pfizer; Sanofi/Regeneron
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Exicure; Novartis; Pfizer; Sanofi/Regeneron
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); exicure (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst)
 
Dirk Schadendorf
Honoraria - 4SC; Amgen; Array BioPharma; Bristol-Myers Squibb; Daiichi Sankyo Japan; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; Nektar; NeraCare GmbH; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi/Regeneron; Sun Pharma; Ultimovacs
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; NEKTAR; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Ann W. Silk
Consulting or Advisory Role - Genzyme; Instil Bio; Merck; Oncosec
Research Funding - Biohaven Pharmaceuticals (Inst); Morphogenesis (Inst); Replimune (Inst); Shattuck Labs (Inst)
 
Anthony J. Olszanski
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Merck; Pfizer; Sanofi; Takeda
Research Funding - Alkermes (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Gan & Lee (Inst); GlaxoSmithKline (Inst); Glyconex (Inst); Immunocore (Inst); Intensity Therapeutics (Inst); Iovance Biotherapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Navire (Inst); Nektar (Inst); OncoSec (Inst); Regeneron (Inst); Seagen (Inst); Sound Biologics (Inst); Spring Bank (Inst); Sumitomo Group (Inst); Takeda (Inst); Targovax (Inst)
(OPTIONAL) Uncompensated Relationships - Takeda
 
Jean-Jacques Grob
Consulting or Advisory Role - Amgen; BMS; Merck KGaA; MSD Oncology; Novartis; Philogen; Pierre fabre; Roche; Roche/Genentech; Sanofi; Sun Pharma
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - BMS; MSD Oncology; Novartis; Pierre Fabre
 
Sekwon Jang
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Genentech; Iovance Biotherapeutics; Macrogenics; Pfizer; Sanofi; Sun Biopharma
 
Jaspreet Singh Grewal
Consulting or Advisory Role - Eisai
Speakers' Bureau - Bristol-Myers Squibb; Ipsen
 
Karl D. Lewis
Honoraria - Array BioPharma; Iovance Biotherapeutics
Consulting or Advisory Role - Array BioPharma; Iovance Biotherapeutics; Merck; Nektar; Regeneron; Roche; Sanofi
Research Funding - Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Kartos Therapeutics (Inst); Merck (Inst); Nektar (Inst); Neon Therapeutics (Inst); OncoSec (Inst); Regeneron (Inst); Replimune (Inst); Roche/Genentech (Inst); Seagen (Inst); Senhwa Biosciences (Inst); Ultimovacs (Inst)
Travel, Accommodations, Expenses - Alkermes; Merck; Neon Therapeutics; Regeneron; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Regeneron; Roche/Genentech
 
Leslie Anne Fecher
Consulting or Advisory Role - Elsevier; Hoosier Cancer Research Network; Via Oncology
Research Funding - Bristol-Myers Squibb (Inst); Kartos Therapeutics (Inst); Pfizer/Array (Inst); Pfizer/EMD Serono (Inst)
Other Relationship - Pfizer/Array
(OPTIONAL) Uncompensated Relationships - American Association of Clinical Endocrinology; ASCO; NCCN
 
Guilherme Rabinowits
Consulting or Advisory Role - Castle Biosciences; Sanofi
 
Celeste Lebbe
Honoraria - Amgen; Bristol-Myers Squibb; Incyte; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Sanofi
Other Relationship - Avantis Medical Systems
 
Annalise Shen
Employment - Abbvie (I); Kartos Therapeutics; Sanofi; Telios
Stock and Other Ownership Interests - Abbvie; GlaxoSmithKline
 
Tiffanie Chan
Employment - Kartos Therapeutics
Stock and Other Ownership Interests - Kartos Therapeutics
 
Jesse S. McGreivy
No Relationships to Disclose
 
Wayne P. Rothbaum
Leadership - Iovance Biotherapeutics
Stock and Other Ownership Interests - Acerta Pharma/AstraZeneca (Inst); Kartos Therapeutics (Inst); Telios (Inst)
Patents, Royalties, Other Intellectual Property - Telios Pharma and Kartos Therapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics; Kartos Therapeutics
(OPTIONAL) Uncompensated Relationships - Kartos Therapeutics (Inst); Telios (Inst)
 
Glenn J. Hanna
Honoraria - Bristol-Myers Squibb; Kura Oncology
Consulting or Advisory Role - Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Exicure; General Catalyst; Kura Oncology; Merck; Naveris; Prelude Therapeutics; Rain Therapeutics; Remix Therapeutics; Sanofi
Research Funding - Actuate Therapeutics (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Conquer Cancer, the ASCO Foundation; Elevar Therapeutics (Inst); Exicure (Inst); Gateway for Cancer Research; Genzyme (Inst); GlaxoSmithKline (Inst); Kartos Therapeutics (Inst); Kite/Gilead (Inst); Kite/Gilead (Inst); NantKwest, (Inst); Regeneron (Inst); Secura Bio (Inst); V Foundation
Expert Testimony - Aaronson Rappaport Feinstein & Deutsch; Ahmuty, Demers, & McManus; Wilson Elser Moskowitz Edelman & Dicker, LLP
 
Ciara Marie Kelly
Employment - Daichii Sankyo (I)
Stock and Other Ownership Interests - daichii sankyo (I)
Consulting or Advisory Role - ChemoCentryx; Exicure; Immunicum; Kartos Therapeutics
Research Funding - AGIOS (Inst); Amgen (Inst); Exicure (Inst); INCYTE (Inst); Kartos Therapeutics (Inst); Merck (Inst); Servier (Inst); xencor (Inst)